Analysts Expect Evolent Health Inc (EVH) Will Announce Quarterly Sales of $192.57 Million

Share on StockTwits

Equities research analysts expect Evolent Health Inc (NYSE:EVH) to announce sales of $192.57 million for the current fiscal quarter, according to Zacks. Ten analysts have provided estimates for Evolent Health’s earnings. The highest sales estimate is $195.00 million and the lowest is $189.80 million. Evolent Health posted sales of $144.51 million in the same quarter last year, which suggests a positive year-over-year growth rate of 33.3%. The firm is scheduled to announce its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Evolent Health will report full year sales of $838.07 million for the current fiscal year, with estimates ranging from $826.33 million to $846.41 million. For the next financial year, analysts forecast that the firm will post sales of $947.17 million, with estimates ranging from $925.50 million to $986.68 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Evolent Health.

Evolent Health (NYSE:EVH) last released its earnings results on Tuesday, May 7th. The technology company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.02. The company had revenue of $197.80 million for the quarter, compared to the consensus estimate of $192.65 million. Evolent Health had a negative return on equity of 4.80% and a negative net margin of 12.52%. Evolent Health’s quarterly revenue was up 41.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.02 earnings per share.

A number of equities research analysts have commented on EVH shares. Zacks Investment Research cut Evolent Health from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. KeyCorp decreased their price target on Evolent Health from $32.00 to $20.00 and set an “overweight” rating on the stock in a report on Monday, March 4th. Finally, TheStreet cut Evolent Health from a “c-” rating to a “d+” rating in a report on Friday, February 22nd. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $26.54.

Hedge funds have recently modified their holdings of the company. Parkside Financial Bank & Trust increased its holdings in shares of Evolent Health by 57.7% in the fourth quarter. Parkside Financial Bank & Trust now owns 3,628 shares of the technology company’s stock worth $72,000 after purchasing an additional 1,327 shares during the last quarter. We Are One Seven LLC bought a new stake in shares of Evolent Health in the fourth quarter worth about $99,000. Jane Street Group LLC bought a new stake in shares of Evolent Health in the third quarter worth about $205,000. Great West Life Assurance Co. Can increased its holdings in shares of Evolent Health by 42.3% in the first quarter. Great West Life Assurance Co. Can now owns 8,754 shares of the technology company’s stock worth $110,000 after purchasing an additional 2,604 shares during the last quarter. Finally, GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in shares of Evolent Health in the first quarter worth about $141,000. 99.96% of the stock is currently owned by hedge funds and other institutional investors.

NYSE:EVH traded down $0.18 on Tuesday, reaching $14.19. 95,340 shares of the company’s stock traded hands, compared to its average volume of 826,189. The company has a quick ratio of 1.96, a current ratio of 1.96 and a debt-to-equity ratio of 0.24. The stock has a market cap of $1.17 billion, a PE ratio of -40.54 and a beta of 1.26. Evolent Health has a 12 month low of $12.09 and a 12 month high of $29.05.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Further Reading: How do analysts define an oversold condition?

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.